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and 1.90.4 cm2; and gradient of 8.13.3 mmHg and 7.63.1 mmHg, at
30 days and 6 months, respectively. Compared with baseline, 76.3% of
patients experienced improvement in NYHA class at 30 days, and
84.9% at 6 months. Permanent pacemaker rates were 11.7% at 30 days,
and 13.4% at 6 months.
CONCLUSIONS The Evolut R TAV is associated with exceptional
safety at 30 days, which continued at 6 months. We plan to report 1-
year outcomes at the time of the meeting.
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BACKGROUND Data on transcatheter aortic valve replacement
(TAVR) failure is limited. The study objective was to determine the
incidence, timing, clinical characteristics and treatment outcomes of
patients diagnosed with TAVR failure attributed to transcatheter heart
valve (THV) thrombosis.
METHODS A retrospective analysis of prospectively raised data
included in a single center TAVR registry. Patients in this 100% follow-
up registry have a predeﬁned echocardiographic and clinical follow-
up schedule (1 month, 6 months,1 year and yearly thereafter or earlier
if symptomatic). THV thrombosis was deﬁned as (1) valve dysfunction
(mean transvalvular gradient >20 mmHg, reduction of the aortic valve
area to <1.2 cm2 or new onset more than mild transvalvular regurgi-
tation) secondary to thrombosis diagnosed based on response to
anticoagulation therapy or typical ﬁndings on imaging modality
(Echo/CT) or (2)mobile mass suspicious of thrombus detected on the
valve, irrespective of dysfunction, and in the absence of infection. The
primary study endpoint was the incidence of THV thrombosis.
RESULTS During the study period (September 2007-March 2015), 588
patients underwent TAVR (CoreValve-305, Sapien XT-124,Sapien 3-
117,Lotus-40,others-2). THV thrombosis was diagnosed in 12(2%) pa-
tients: Sapien XT-9, Sapien3-1 and Lotus-2. Thrombosis was not
observed in any of the CoreValve patients. The mean age was
798years and the majority were females (n¼10, 83.3%). The median
time to thrombosis detection was 180 days(interquartile range, IQR 23-
472). 3 patients were diagnosed early (within 1 month) after TAVR, of
which 2 had a Lotus valve. In another 3 patients, thrombosis was
diagnosed late (>1 year after TAVR). Half of the patients had no wors-
ening symptoms at the time of diagnosis. In symptomatic subjects,
exertional dyspnea with change in NYHA class was the most common
mode of presentation (n¼5). 1 patient presented with stroke. Treatment
at the time of detection of thrombosis was dual antiplatelet therapy in
11 and aspirin monotherapy in 1. No cases of THV thrombosis were seen
in patients discharged on oral anticoagulation. Mean aortic valve
pressure gradient was elevated in 10(83%) of thrombosis patients; mean
transvalvular gradient for all subjects being 3616mmHg. Other echo-
cardiographic ﬁndings included thrombotic mass on the leaﬂets (n¼7,
58.3%) and thickening of leaﬂets with reduced mobility. Median serum
NT-proBNP level was 1318 pg/ml (IQR 1123-1605). After treatment with
anticoagulants, mean aortic gradient and NT-proBNP levels reduced
signiﬁcantly. There were no deaths related to valve thrombosis.
CONCLUSIONS THV thrombosis is a rare but an important cause of
TAVR failure, most frequently detected at a median of 180 days after
the procedure. Patients may present with exertional dyspnoea and/orincreased transvalvular gradients. Anticoagulation is effective in
improving gradients and clinical status. Optimal antithrombotic
therapies after TAVR need to be deﬁned, and randomized controlled
trials are needed.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic
KEYWORDS TAVI, Thrombosis, Transcatheter aortic valve replacement
TCT-100
Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal
Disease: One Year Outcomes from the CoreValve US Expanded Use Study
Daniel O’Hair,1 George Petrossian,2 Tanvir Bajwa,3 Stanley J. Chetcuti,4
G Michael Deeb,4 Neal Kleiman,5 Michael J. Reardon6
1Aurora St. Luke’s Medical Center, Milwaukee, WI; 2St. Francis
Hospital, Roslyn, NY; 3ACS, Aurora Sinai/St. Luke’s Med Ctrs, Univ
Wisconsin School of Medicine and Public Health, Milwaukee, WI;
4University of Michigan, Ann Arbor, MI; 5Houston Methodist DeBakey
Heart and Vascular Center, Houston, United States; 6Houston
Methodist DeBakey Heart & Vascular Center, Houston, TX
BACKGROUND End stage renal disease (ESRD) poses unique chal-
lenges in the treatment of patients with severe aortic stenosis. While
surgical valve replacement in patients with ESRD has been associated
with an increase in the risk of morbidity and mortality, the results
from transcatheter valve replacement have not been clearly deﬁned.
METHODS The CoreValve US Expanded Use Study is a prospective,
nonrandomized trial of transcatheter aortic valve replacement (TAVR)
in extreme risk (ER) patients with ESRD or other speciﬁc comorbidities
excluding them from the Pivotal Trial. Patients with ESRD who were
deemed to be ER by two surgeons, had symptoms attributable to
aortic stenosis, had an aortic valve area of 0.8 cm2 (or aortic valve
area index  0.5 cm2), and either a mean gradient 40 mmHg or peak
velocity  4.0 m/s with one year of follow up are included in this
report. The primary endpoint for the study was all-cause mortality or
major stroke at 12 months. One year outcomes are compared with
patients enrolled in the CoreValve ER US Pivotal Trial and an objective
performance goal (OPG) pre-speciﬁed for the ER US Pivotal Trial.
RESULTS Fifty-four patients with ESRD underwent TAVR with Cor-
eValve as part of the US Expanded Use Study and have reached one year
follow up. Mean STS-PROM was 17.1  8.4 in ESRD patients versus 10.3
 5.5 in ER US Pivotal patients. The rate of all-cause mortality or major
stroke at 12 months was 26% in the ER US Pivotal Trial, 35% in the ESRD
Expanded Use Study, and compared with 43% which is the ER US
Pivotal Objective Performance Goal. Initial 30 day all-cause mortality
was 7.4% (8.4 % in US Pivotal) and 1 year was 35.2% in ESRD patients.
Any stroke or TIA at 1 year was 1.9%, major vascular injury was 3.7% and
new permanent pacemaker rate was 22.9%. Valve performance at one
year was comparable to post-procedure in effective oriﬁce area (1.82
cm2 post-procedure v. 1.81 cm2 1 year) and mean gradient (9.8 mmHg
post-procedure v. 9.2mmHg 1 year).
CONCLUSIONS Early mortality in patients with ESRD is comparable to
ER patients without ESRD but one year data suggest a higher mortality
likely due to comorbid conditions. Stroke and major vascular injury
were infrequent and valve durability is maintained at one year.
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BACKGROUND A peri-procedural stroke rate of 2-7% remains a major
complication after transcatheter aortic valve replacement (TAVR) and
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reduce the stroke rate.
METHODS 133 patients underwent TAVR procedures using the Claret
Cerebral Protection System (CPS; Claret Medical, Inc., Santa Rosa, CA)
to guard against peri-procedural strokes. Various TAVR prostheses
were used (55 Sapien 3, 36 Sapien/Sapient XT, 28 Corevalve/Evolut R,
8 Portico, 4 JenaValves, 1 Centera, 1 Direct Flow) as well as different
access routes (transfemoral 119, transapical 8, transaxillary 6). In 21
cases, valve-in-valve procedures were performed in degenerated
surgical aortic bioprostheses; 9 patients had a left atrial appendix
(LAA) thrombus. Mean patient age was 80  8 years; mean logistic
EuroSCORE of 27  18%. Clinical follow-up was obtained at 3 days
after the intervention and at discharge (mean 10 days). Histological
analyses were performed in 52 patients by the CVPath Institute in
Gaithersburg, MD (42 additional analyses are still in progress).
RESULTS Stroke rate after TAVR was 2.3% (3/133) at 3 days post TAVR;
all were major strokes. Sapien 3 (n¼2) and Evolut R (n¼1) prostheses
had been used in these patients. In 2 patients the cerebral protection
device was not positioned as intended (one malpositioning, one posi-
tioning not possible due to kinking of the truncus brachiocephalicus)
and in 1 patient the device dislocated during peri-procedural resusci-
tation and additional deﬁbrillation in the presence of LAA thrombus.
Histological investigations showed debris in the ﬁlters in 96% of cases.
Debris was more common in the distal (87%) than in the proximal ﬁlter
(73%). Acute thrombus was the most common type of debris found in
56% of ﬁlters. In 30% of all cases, valve and arterial wall tissue and
calciﬁcation was found. Organized thrombus was found in 12%, while
foreign material was found in 7% of all cases. The percentages of
different types of debris were similar in proximal and distal ﬁlters.
Foreign material was captured in 13% and 17% (proximal/distal) of ﬁl-
ters but was not present when using the Sapien 3 prosthesis.
CONCLUSIONS Feasibility and safety of the Claret CPS was docu-
mented in these 133 patients. Histopathological analyses showed high
overall debris capture and retrieval rates, with prevalence of thrombus
over valve and arterial wall tissue, calciﬁcation and foreign material.
Sapien 3 implantations showed no foreign material in the ﬁlters. Pro-
cedural stroke rate was low at 2.3%, occurring only when the cerebral
protection device was not properly placed. Stroke rate for optimally
positioned devices was 0% in this registry, which included also patients
with LAA thrombus and cardiogenic shocks. Further experience and
investigation is needed to ensure optimal positioning, to quantify any
reduction in new cerebral lesions using protection, and to deﬁne which
patients are at the higher risk for cerebral embolization.
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BACKGROUND Transcatheter aortic valve-in-valve (ViV) implantation
into degenerated bioprostheses has become an alternative toreoperative aortic valve replacement. Remaining challenges relate to
residual stenosis after implantation. We report on the ﬁrst compre-
hensive analysis of clinical outcomes of SAPIEN 3 (S3) used for ViV
and compare to early generation SAPIEN XT (SXT) balloon-expandable
device.
METHODS A total of 404 ViV procedures using SXT or S3 balloon
expandable devices from the Valve-in-Valve International Data
(VIVID) registry were included. Groups were matched for baseline
characteristics and surgical bioprosthesis size and type. Subsequently,
a group of 48 patients that underwent S3 implantation was compared
to a 2:1 matched group of 96 patients that underwent SXT implanta-
tion. Procedural and clinical outcomes were deﬁned by Valve Aca-
demic Research Consortium II (VARC-II).
RESULTS Patients included in the matched groups had an average age
of 75.611.1yrs and 56.9% were male. Failure mode was stenosis,
regurgitation and the combination of both in 35.4%, 33.3% and 29.3%,
respectively. Mean STS PROM was 97.4%. Average bioprostheses
label size was similar between the groups: 23.71.8 mm (S3) vs.
242.1 mm (SXT), p¼0.44. Small surgical valves (label size21mm)
were apparent in 18.8% of S3 vs. 19.2% of SXT cases (p¼0.88). Pro-
cedures were performed using transfemoral access in 87.5% (S3) vs.
80.2% of (SXT, p¼0.28). Implanted transcatheter valve sizes were
23.61.3 mm (S3) vs. 24.61.9 mm (SXT, p¼0.001). There was a trend
towards lower 30-day mortality in the S3 group (0% vs. SXT 7%, p ¼
0.08). Rates of adverse events were low: coronary obstruction in 0%
(S3) vs. 1.1% (SXT, p ¼ 0.48), major stroke in 0% (S3) vs. 1.1% (SXT, p ¼
0.48). In patients without a permanent pacemaker at baseline, a trend
towards higher rates of pacemaker implantation was observed after S3
ViV (8.3% vs. SXT 2.1%, p¼0.08). Residual aortic regurgitation of
more than mild degree was noticed in 2.1% (S3) vs. 9.5% (SXT, p¼0.1)
of patients. Mean gradients after implantation were similar:
18.18.4 mm (S3) vs. 17.69.2 mm (SXT, p¼0.76), as was the rate of
elevated post procedural gradients: 20mmHg 38.3% (S3) vs. 34.8%
(SXT, p¼0.69), 40mmHg 4.3% (S3) vs. 6.7% (SXT, p¼0.56). The
incidence of severe patient-prosthesis mismatch (32.4% [S3] vs. 28.1%
[SXT], p¼0.67) was similar but a trend towards greater effective oriﬁce
areas was observed after SXT implantation (1.40.4 mm [S3] vs.
1.50.5 mm [SXT], p¼0.1).
CONCLUSIONS In this multicenter experience, excellent clinical
outcomes with low complication rates were achieved after aortic ViV
implantation with the S3 transcatheter heart valve. However, post-
procedural gradients remained elevated with this second generation
device and similar to early generation device, underlining the need for
careful patient selection in order to avoid severe patient-prosthesis
mismatch after ViV implantation.
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BACKGROUND Oral antiplatelet medications are routinely adminis-
tered to patients following TAVR, however, there are limited data on
the ideal antithrombotic treatment strategy or the patterns of medi-
cation use and outcomes in the U.S.
METHODS Using the STS/ACC TVT Registry we evaluated patients
without pre-operative atrial ﬁbrillation undergoing TAVR from 2011 to
2014. Clinical outcomes included death, bleeding, and stroke at 1 year
of follow up.
RESULTS Overall, 5,974 patients treated at 298 hospitals were
analyzed. Of these, 69% (n¼4,132) were discharged on combined
aspirin and a clopidogrel (DAPT), 28% (n¼1,344) on aspirin alone,
5%(n¼294) on clopidogrel alone, and 3% (n¼ 204) on no antiplatelet
therapy. Antiplatelet prescribing patterns varied signiﬁcantly at the
hospital level (Figure). Patients discharged on DAPT were similar with
respect to age (84 vs 84 years), gender (51.6% vs. 53.1% female), and
most comorbid illnesses, but had higher rates of CAD (67.1% vs.
55.7%), and lower STS PROM risk scores (6.1 vs. 6.4). Regarding
clinical outcomes, unadjusted 1 year death (13.3% vs. 16.5%;
p<0.001) and bleeding rates (15.4% vs. 19.6%; p¼0.001) were lower
in patients prescribed DAPT after TAVR, while stroke rates were not
